Astellas Pharma and Ambit Biosciences will end their collaboration for the joint development and commercialization of FMS-like tyrosine kinase-3 (FLT3) inhibitors, including quizartinib, effective September 3, 2013. The companies will transfer current development activities to Ambit, which will regain all rights and continue the quizartinib clinical program in acute myeloid leukemia (AML).   “While our decision is based on strategic reasons, we are proud of our collaborative work with Ambi...